Jefferies Group LLC Bluebird Bio, Inc. Transaction History

Jefferies Group LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.94 - $5.23 $179,263 - $318,894	-60,974 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $248,164 - $646,324	60,974 New	60,974 $3,000
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $108,240 - $132,540	-6,000 Closed	0 $0
Q1 2021 Sep 21, 2023	BUY	$16.59 - $33.89 $99,540 - $203,340	6,000 New	6,000 $117,000
Q1 2021 May 14, 2021	SELL	$16.59 - $33.89 $25,863 - $52,834	-1,559 Reduced 20.62%	6,000 $181,000
Q1 2020 May 15, 2020	BUY	$26.16 - $63.5 $109,636 - $266,128	4,191 Added 124.44%	7,559 $347,000
Q3 2019 Nov 13, 2019	SELL	$59.47 - $93.1 $85,161 - $133,319	-1,432 Reduced 29.83%	3,368 $309,000
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $204,768 - $284,067	-2,700 Reduced 36.0%	4,800 $611,000
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $483,300 - $780,825	7,500 New	7,500 $1.18 Million
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $1.26 Million - $1.67 Million	-14,200 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$99.64 - $127.59 $1.3 Million - $1.66 Million	12,998 Added 1081.36%	14,200 $2.23 Million
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $127,171 - $181,429	1,202 New	1,202 $205,000

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $27M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.